Unknown PHASE1/PHASE2 INTERVENTIONAL NCT03398967

A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma

Phase I/II Study to Evaluate Treatment of Relapsed or Refractory Leukemia and Lymphoma With Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19 and CD20 or CD22

Sponsor: Chinese PLA General Hospital

Conditions B Cell Leukemia B Cell Lymphoma

Interventions Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells

Updated 6 times since 2018 Last updated: Jan 8, 2018 Started: Jan 2, 2018 Primary completion: May 20, 2022 Completion: May 20, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates B Cell Leukemia and B Cell Lymphoma and is currently ongoing. Chinese PLA General Hospital leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2022 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Jun 2022 [monthly]

Recruiting PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 1 earlier version

Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Jan 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese PLA General Hospital

Data source: Chinese PLA General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China